Who is sponsoring NCT05165823?

NCT05165823 is sponsored by Regional Hospital Holstebro.

What drugs are being tested in NCT05165823?

Interventions in NCT05165823: Sodium restriction.

What condition does NCT05165823 study?

NCT05165823 studies Hypertension,Essential.

Is NCT05165823 still recruiting?

NCT05165823 is currently completed. Last updated 22 September 2023.

Last reviewed 2023-09-22 · How we verify

NCT05165823: VASA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Significance of Sodium Balance and the Value of Salt-blood Test in Identifying Salt Sensitive Patients

Completed NA Last updated 22 September 2023

What this trial tests

NA trial testing Sodium restriction in Hypertension,Essential in 72 participants. Completed in 26 July 2023.

Timeline

8 February 2022

Primary endpoint
5 July 2023

26 July 2023

Quick facts

Lead sponsor	Regional Hospital Holstebro
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	72
Start date	8 February 2022
Primary completion	5 July 2023
Estimated completion	26 July 2023
Sites	1 location across Denmark

Drugs / interventions tested

Sodium restriction

Conditions studied

Hypertension,Essential — all drugs for Hypertension,Essential →

Sponsor

Regional Hospital Holstebro

Who can join

18 and older, any sex, with Hypertension,Essential. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a randomized controlled trial with 72 patients with hypertension examining the effects on blood pressure of sodium restriction and whether the blood analysis Salt-blood test is associated to a decrease in blood pressure. Patients will be randomized 2:1 to either sodium restriction or usual diet for 4 weeks. Baseline measures will be done before intervention and outcome measures after the 4 weeks.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Self-Performed Dietary Sodium Reduction and Blood Pressure in Patients With Essential Hypertension: A Randomized Clinical Trial.
Duus CL, Nielsen SF, Hornstrup BG, Mose FH, et al · · 2024 · cited 6× · PMID 38842286 · DOI 10.1161/jaha.124.034632
Dietary Sodium Reduction Reveals Aldosterone Dysregulation in Patients With Essential Hypertension
Duus C, Nielsen S, Hornstrup B, Mose F, et al · · 2026

Verify or expand the search:

Other recruiting trials for Hypertension,Essential

Currently open trials in the same condition.

NCT05067998 — The Benefits of Natural Medicine, Vitamin IV Therapy and Supplements: Maintaining Good Health Through Nature · recruiting
NCT06461273 — Food is Medicine vs Lifestyle Medicine For Cardiovascular Kidney Metabolic (CKM) Syndrome · NA · active not recruiting
NCT06205628 — Safety, Tolerability, PK and PD of ADX-850 in Participants With Hypertension · Phase 1 · active not recruiting
NCT04505618 — Optical Coherence Tomography Angiography in Subjects With Retinal Vascular Disease · NA · recruiting
NCT04625569 — Genetic of Response to Acute Saline Load Test in Hypertension (Naload) · recruiting

Other Regional Hospital Holstebro trials

Trials by the same sponsor.

NCT04363554 — The Kidneys Ability to Concentrate and Dilute Urine in Patients With Autosomal Dominant Polycystic Kidney Disease · NA · completed
NCT06019026 — Five-year Migration Pattern and Bone Mineral Density for the Tri-Lock and Summit Femoral Stems. · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05165823 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Regional Hospital Holstebro
Last refreshed: 22 September 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05165823.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing